2024-03-28T11:23:55Zhttps://www.tdx.cat/oai/requestoai:www.tdx.cat:10803/72342024-03-15T10:57:25Zcom_10803_236col_10803_690278
nam a 5i 4500
genotip
haplotip
gen resistència multisubstància (ABCB1)
gen miocardina (MYOCD)
gen
gen candidat
farmacogenòmica
fenotip
farmacogenètica
farmacodinàmica
farmacocinètica
estereoselectivitat
epistaxi
enzim
enantiòmer
3-diphenyl-1-pyrrolidine
5-dimethyl-3
3-diphenylpyrrolidine
electroforesi
EMDP
2-ethyl-5-methyl-3
2-ethylidene-1
dopamina
EDDP
criptocrom 1 (CRY1)
desintoxicació
comorbiditat psiquiàtrica
Citocrom P4503A5
Citocrom P4503A4
Citocrom P4502D6
Citocrom P4502B6
Citocrom P4502C19
Citocrom P4502C9
Citocrom P4501A2
Citocrom P450
biodisponibilitat
Alel
addicció
abstinència
withdrawal
vulnerability
stereoselectivity
substance abuse
single nucleotide polymorphism (SNP)
psychiatric comorbidity
replacement therapy
polymorphism
pharmacogenomics
pharmacokinetics
phenotype
pharmacogenetics
pharmacodynamics
opioid dependence
opioid
opiate
neurotrophins
neurotransmitter
Myocardin gene (MYOCD)
resistant gene 1 (ABCB1)
multidrug
methadone
mu opioid receptor
metabotropic glutamate receptors
maintenance treatment
Isomers
heroin (diacetylmorphine)
Haplotype
Genotype
gene
Epistasis
Enzyme
Enantiomer
3-diphenyl-1-pyrrolidine
2-ethyl-5-methyl-3
EMDP
Electrophoresis
3-diphenylpyrrolidine
5-dimethyl-3
dopamine
EDDP
2-ethylidene-1
detoxification
Cytochrome P4503A5
Cytochrome P4503A4
Cytochrome P4502D6
Cytochrome P4502C9
Cytochrome P4502C19
Cytochrome P4502B6
Cytochrome P4501A2
Cytochrome P450
Cryptochrome 1 gene (CRY1)
craving
Complex Disease
candidate gene
allele
Brain Derived Neurotrophic factor (BDNF)
addiction
heroïna (diacetilmorfina)
isòmers
metadona
neurotransmissor
neurotrofines
opiacis
polimorfisme
polimorfisme de nucleòtid únic (SNP)
receptor metabotròpic del glutamat
receptor opioide mu
tractament de manteniment
tractament substitutiu
trastorn per ús de substàncies
vulnerabilitat
Pharmacogenomic study of oppioid addicts in methadone treatment / Francina Fonseca Casals
[Barcelona] :
Universitat Pompeu Fabra,
2011
Accés lliure
http://hdl.handle.net/10803/7234
cr |||||||||||
AAMMDDs2011 sp ||||fsm||||0|| 0 eng|c
978-84-694-3916-6
Fonseca Casals, Francina,
autor
Programa de doctorat en Biomedicina,
degree
Tesi
Doctorat
Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut
2010
Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut
Tesis i dissertacions electròniques
Torrens, Marta,
supervisor acadèmic
Torre Fornell, Rafael de la,
supervisor acadèmic
TDX
Although the well established efficacy of methadone maintenance treatment (MMT) in the opioid dependence disorder, there is a group of patients that are poor responders. The study of the influence of methadone pharmacodynamics and pharmacokinetics in dose requirements and program outcome remains still controversial. The aim of this dissertation is to study the pharmacodynamic and pharmacokinetic factors involved in the methadone maintenance treatment efficacy. <br/>The study recruited opioid dependence patients (DSM-IV criteria) from a MMT community program. Patients were clinically assessed and blood samples were obtained in order to evaluate methadone plasma concentrations of (R,S)-, (R) and (S)- methadone. Allelic variants of genes encoding the following proteins were assessed: BDNF, OPRM1, MYOCD, mGluR6, mGluR8, CRY1, NR4A2, 1q31.2 (rs965972), 2q21.2 (rs1867898), CYP3A5, CYP2D6, CYP2B6, CYP2C9, CYP2C19 and P-glycoprotein. Responders and non-responders were defined by means of illicit opioid consumption detected in random urinalyses. <br/>Differences in response status were found depending on different single nucleotide polymorphisms (SNPs of genes encoding for BDNF, MYOCD and GRM6. The CYP2D6 metabolizing phenotype was associated with response to MMT, and also with methadone dosage requirement and methadone plasma concentrations.
f
ES-BaCBU
cat
rda
ES-BaCBU
text
txt
rdacontent
informàtic
c
rdamedia
recurs en línia
cr
rdacarrier